Author

C. Tummler

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:chromatin & epigenetic regulation· 1 Research Focus:drug response / drug discovery· 1 Assay:long-read sequencing· 1 Assay:metabolomics· 1 Assay:proteomics· 1

Frequent Co-Authors

J. I. Johnsen· 2 shared P. Kogner· 2 shared A. Alchahin· 1 shared A. Djos· 1 shared A. Mendez· 1 shared B. Embaie· 1 shared C. Bartenhagen· 1 shared C. Dyberg· 1 shared

Activity by Year

2021-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

J. I. Johnsen

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

METTL3 drives telomere targeting of TERRA lncRNA through m6A-dependent R-loop formation: a therapeutic target for ALT-positive neuroblastoma

R. Vaid, K. Thombare, A. Mendez, R. Burgos-Panadero, A. Djos, D. Jachimowicz, K. Ihrmark Lundberg, C. Bartenhagen, N. Kumar, C. Tummler, C. Sihlbom, S. Fransson, J. I. Johnsen, P. Kogner, T. Martinsson, , T. Mondal

This study shows METTL3 modifies TERRA lncRNA with m6A, promoting R-loop formation that targets TERRA to telomeres, and inhibiting METTL3 disrupts this process in ALT+ neuroblastoma cells.

Nucleic Acids Research · Mar 21, 2024Peer-reviewedCancer Biology

DHODH is an independent prognostic marker and potent therapeutic target in neuroblastoma

T. K. Olsen, C. Dyberg, B. Embaie, A. Alchahin, J. Milosevic, J. Otte, C. Tummler, I. H. Myrberg, E. M. Westerhout, J. Koster, R. Versteeg, P. Kogner, J. I. Johnsen, D. B. Sykes, N. Baryawno

This study identifies DHODH as a prognostic marker and therapeutic target in neuroblastoma, showing its inhibition improves survival in preclinical models and suggests combination therapy with temozolomide.

bioRxiv · Sep 25, 2021Cancer Biology